Announcement in CES 2022 (01.05)
- Pharmulator Ver. 2.5
- PharmVAC Ver. 1.0
MOU with Qunova to develop new drugs utilizing Quantum Computing technology (02.22)
Licensing agreement with Redipharm to license out anti-cancer drug candidate (03.04)
Licensing agreement with NeuroVenti to license out Autism Spectrum Disorder drug candidate (04.29)
Signed up Korean Chamber of Vaccine Developers and Manufacturing Companies (06.23)
Held PharmCADD AI Drug Discovery Conference 2022 (07.13)
Strategic collaboration with ISU ABXIS to develop the treatment for neurofibromatosis type 1 (NF1) (08.30)
Certified as an IP management company (10.13)
Strategic collaboration with KYNOGEN to discover anti-cancer drug candidates (01.22)
Established PharmCADD India PVT Ltd. (05.14)
Established PharmCADD USA Inc. (05.17)
MOU with Indian Institute of Technology-Hyderabad (IITH) to develop compounds (06.09)
Exhibited “Pharmulator” at BIO KOREA 2021 (06.09 ~ 06.11)
Strategic collaboration with KRICT to develop anti-cancer drug (07.01)
Strategic collaboration with NeuroVenti to develop Autism spectrum disorder drug (07.06)
Strategic collaboration with CNRS to develop DDS and PROTAC (07.12)
Partnership with Korea Investment & Securities to prepare KOSDAQ listing (08.26)
Moved headquarters (331, Jungang-daero, Dong-gu, Busan, Republic of Korea) (09.15)
MOU with NeuroVenti and MeDKit to develop digital therapeutics for Autism spectrum disorder (09.15)
MOU with University of Groningen (01.02)
Exhibited “Pharmulator Ver. 1.0” at CES 2020 (01.07)
"Pharmulator" Domestic Showcase at COEX (02.04)
CEO gave a special lecture in the national pharma-bio forum (04.23)
MOU with Pusan National University to develop AI-based novel drug (05.06)
Joined COVID-19 vaccine development consortium (05.29)
Participated in BIO USA 2020 (06.09)
MOU with Korea Institute of Radiological Medical Sciences (KIRAMS) (08.31)
Launched “Pharmulator Ver. 2.0” (08.31)
Licensing agreement of COVID-19 mRNA vaccine sequences (09.09)
Strategic collaboration with ADEL to develop novel Alzheimer’s disease drug (09.28)
Strategic collaboration with Huons to optimize drug candidate (PROTAC) (12.16)
Founded : 2019.3.5. (Headquarters : in Busan)
Pharmulator System Development
Seoul Branch (3.20)
Venture Business Certification (8.21)
MOU with Kosin Gospel University Hospital (10.21)
